What contribution can biosimilars make to reduce the burden on healthcare systems and, above all, for the benefit of patients? An interview with Formycon CEO Dr. Stefan Glombitza about these topics and Formycon’s focus as a pure-play biosimilar company was recently published in the Bio Deutschland e.V. yearbook. The interview is available here (in German).